Jennifer L Beaumont

13PUBLICATIONS
44CO-AUTHORS
Pharmaceutical delivery technologiesPredictive and prognostic markersRheumatology and arthritisCancer therapy (excl. chemotherapy and radiation therapy)Psychosocial aspects of childbirth and perinatal mental health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Mar 06, 2025
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.

April W Armstrong, Matthias Augustin, Jennifer L Beaumont

|Jul 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.

April W Armstrong, Matthias Augustin, Jennifer L Beaumont

|Jan 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.

Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes

|May 01, 2023
Integrating PROMIS Measures in a Treat-to-Target Approach to Standardize Patient-Centered Treatment of Rheumatoid Arthritis.

George J Greene, Jennifer L Beaumont, Emily J Bacalao

|Jun 23, 2021
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.

Larysa Sanchez, Xavier Leleu, Jennifer L Beaumont

|May 31, 2021
Targeted eHealth Intervention to Reduce Breast Cancer Survivors' Fear of Recurrence: Results From the FoRtitude Randomized Trial.

Lynne I Wagner, Janet A Tooze, Daniel L Hall

Pageof 3

Frequent Collaborators

3 joint publications

Amy Waterman

2 joint publications

Subhashis Banerjee

2 joint publications

Stacie Hudgens

2 joint publications

Tan P Pham